Anal Carcinoma in Patients with Crohn's Disease: Three Cases Report and Literature Review
نویسندگان
1 Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang, University, Hangzhou, Zhejiang province, China; Inflammatory Bowel Disease Center of Sir Run Run Shaw Hospital, Hangzhou, Zhejiang province, China
2 Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang, University, Hangzhou, Zhejiang province, China; Inflammatory Bowel Disease Center of Sir Run Run Shaw Hospital, Hangzhou, Zhejiang province, China
3 Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang, University, Hangzhou, Zhejiang province, China; Inflammatory Bowel Disease Center of Sir Run Run Shaw Hospital, Hangzhou, Zhejiang province, China
4 Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang, University, Hangzhou, Zhejiang province, China; Inflammatory Bowel Disease Center of Sir Run Run Shaw Hospital, Hangzhou, Zhejiang province, China
doi
10.32592/ircmj.2023.25.2.2370چکیده
Background: Anal cancer in patients with Crohn's disease (CD) is rare, and the relationship between infliximab and anal cancer is not clear yet. The present study aimed to report three patients with CD complicated with anal cancer who used infliximab with their basic features. Case presentation: Three cases were reported, including two females and one male, aged 29-56 years old. All of them developed perianal lesions during the period of Crohn's disease. All three patients had used infliximab for Crohn's disease before the diagnosis of anal cancer, except one patient who stopped using infliximab three times due to allergy; the other two patients had used infliximab until the diagnosis of anal cancer. Two patients had a good prognosis with early therapeutic intervention. Conclusion: Based on the results, Chinese and Western patients with Crohn's disease who developed anal carcinoma had similar features. Conventional perianal evaluation is important in patients with Crohn's disease. The association between infliximab therapy and anal cancer has not been fully established and needs to be fully evaluated before the use of infliximab in Crohn's disease.
